LNTH Q2 2025 Earnings
Reported Aug 6, 2025 at 7:39 AM ET · SEC Source
Q2 25 EPS
$1.57
MISS 6.29%
Est. $1.68
Q2 25 Revenue
$378.0M
MISS 2.55%
Est. $387.9M
vs S&P Since Q2 25
+91.3%
BEATING MARKET
LNTH +107.3% vs S&P +15.9%
Market Reaction
Did LNTH Beat Earnings? Q2 2025 Results
Lantheus delivered a disappointing second quarter, missing on both the top and bottom lines as competitive pressure on its flagship imaging agent weighed heavily on results. The radiopharmaceutical company posted adjusted diluted EPS of $1.57, fallin… Read more Lantheus delivered a disappointing second quarter, missing on both the top and bottom lines as competitive pressure on its flagship imaging agent weighed heavily on results. The radiopharmaceutical company posted adjusted diluted EPS of $1.57, falling 6.29% short of the $1.68 consensus estimate, while revenue slipped 4.1% year-over-year to $378.05 million against expectations of $387.94 million. The primary culprit was PYLARIFY, the company's PSMA PET imaging agent, where an 8.3% sales decline to $250.64 million reflected an increasingly crowded competitive landscape. Lantheus spent much of the quarter reshaping its portfolio through acquisitions, closing its purchase of Evergreen Theragnostics and subsequently acquiring Life Molecular Imaging to broaden its pipeline into Alzheimer's diagnostics and neuroendocrine tumors. Those moves came at a cost to the outlook; full-year 2025 revenue guidance was cut to $1.48 billion to $1.51 billion and adjusted EPS guidance to $5.50 to $5.70, well below prior targets, sending shares to a 52-week low in the aftermath.
Key Takeaways
- • PYLARIFY sales declined 8.3% due to increased competition in the PSMA PET landscape
- • DEFINITY sales grew 7.5% year-over-year
- • Strategic partnerships and other revenue increased 32.8%
- • GAAP net income benefited from unrealized gains on equity securities versus losses in prior year
- • Acquisition, integration and divestiture-related costs of $22.9 million impacted GAAP results
LNTH YoY Financials
Q2 2025 vs Q2 2024, source: SEC Filings
LNTH Revenue by Segment
With YoY comparisons, source: SEC Filings
“In the second quarter and the month thereafter, we completed the acquisitions of both Evergreen Theragnostics and Life Molecular Imaging – key steps in executing our strategy to expand capabilities across the radiopharmaceutical value chain, diversify revenue, including with Neuraceq, and drive future growth. At the same time, we navigated increased competition in the PSMA PET landscape, which impacted PYLARIFY performance. We are taking actions to reinforce PYLARIFY's clinical differentiation and support the value of our PSMA PET franchise.”
— Brian Markison, Q2 2025 Earnings Press Release
LNTH Earnings Trends
LNTH vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
LNTH EPS Trend
Earnings per share: estimate vs actual
LNTH Revenue Trend
Quarterly revenue: estimate vs actual
LNTH Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $1.23 | $1.46 | +18.78% | $377.3M | +6.46% |
| Q4 25 BEAT FY | $1.17 | $1.67 | +42.92% | $406.8M | +10.83% |
| FY Full Year | — | $6.08 | — | $1.54B | — |
| Q3 25 BEAT | $1.27 | $1.27 | +0.24% | $384.0M | +5.37% |
| Q2 25 MISS | $1.68 | $1.57 | -6.29% | $378.0M | -2.55% |